Literature DB >> 7597310

Management of human immunodeficiency virus-associated malignancies.

M A Conant1.   

Abstract

A number of malignancies which have been seen with other immunodeficiency diseases have appeared in patients immunosuppressed by the human immunodeficiency virus (HIV) infection. These include Kaposi's sarcoma, lymphomas, superficially spreading basal cell carcinomas, and squamous cell carcinomas. The fact that Kaposi's sarcoma is the most common of these malignancies and is seen almost exclusively among homosexual men remains an enigma. The dermatological treatment of Kaposi's sarcoma includes observation, surgical excision, radiation therapy, interlesional chemotherapy, and topical liquid nitrogen. When the disease becomes more aggressive, systemic chemotherapy, using a combination of chemotherapeutic agents, will often slow disease progression. It is essential that the chemotherapy be given in a dose that will slow the course of the malignancy, but will not further immunosuppress the patient. The treatment of lymphomas in HIV-infected patients has been less than satisfactory, with a high mortality rate. Aggressive therapy of these lymphomas using combination therapy has been the most successful in increasing survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597310     DOI: 10.1007/978-3-642-78771-3_34

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  2 in total

1.  Primary Kaposi's sarcoma of the nasal cavity not associated with AIDS.

Authors:  Ioannis Venizelos; Charalambos Andreadis; Zoi Tatsiou
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

2.  Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report.

Authors:  Jun-Yeong Seo; Kee-Yong Ha; Min-Up Kim; Yoon-Chung Kim; Young-Hoon Kim
Journal:  J Med Case Rep       Date:  2014-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.